Prevention of murine EAE by oral hydrolytic enzyme treatment

Journal of Autoimmunity

Volumn 12, Issue 3, 1999, Pages 191-198

  Targoni, Oleg S ^a   Tary Lehmann, Magdalena ^a   Lehmann, Paul V ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Accessory molecules; EAE; Enzyme therapy; Phlogenzym; T cell activation threshold

Indexed keywords

BROMELAIN; PHLOGENZYM; RUTOSIDE; TRYPSIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; DRUG USE; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

EID: 0032926775     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.1999.0271     Document Type: Article

References (46)

1. Cornell R., Walker W.A., Isselbacher K.J. Small intestinal absorption of horseradish peroxidase. Lab. Invest. 25:1971;42-48.
2. Washaw A.L., Walker W.A., Cornell R., Isselbacher K.J. Small intestinal permeability to macromolecules. Transmission of horseradish peroxidase into mesenteric lymph and portal blood. Lab. Invest. 25:1971;675-684.
3. Husby S., Jensenius J.C., Svehag S.E. Passage of undegraded dietary antigen into the blood of healthy adults. Further characterization of the kinetics of uptake and the size distribution of the antigen. Scand. J. Immunol. 24:1986;447-452.
4. Bruce M.G., Ferguson A. The influence of intestinal processing on the immunogenicity and molecular size of absorbed, circulating ovalbumin in mice. Immunology. 59:1986;295-300.
5. Bruce M.G., Ferguson A. Oral tolerance produced by gut-processed antigen. Adv. Exp. Med. Biol. 216:1987;721-731.
6. Neutra M.R., Pringault E., Kraehenbuhl J.P. Antigen sampling across epithelial barriers and induction of mucosal immune responses. Annu. Rev. Immunol. 14:1996;275-300.
7. Weiner H.L., Friedman A., Miller A., Khoury S.J., Al-Sabbagh A., Santos L., Sayegh M., Nussenblatt R.B., Trentham D.E., Hafler D.E. Oral tolerance: immunologic mechanism and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu. Rev. Immunol. 12:1994;809-837.
8. Rollwagen F.M., Baqar S. Oral cytokine administration. Immunol. Today. 17:1996;548-550.
9. Yoshino S. The preventive effect of oral administration of type I interferon on collagen-induced arthritis in rats. Exp. Mol. Pathol. 62:1995;123-130.
10. Schafer T.W., Lieberman M., Cohen M., Came P.E. Interferon administered orally: protection of neonatal mice from lethal virus challenge. Science. 176:1972;1326-1327.
11. Fleischmann W.R. Jr., Koren S. Orally administered interferons exert their white blood cell suppressive effects via a novel mechanism. Proc. Soc. Exp. Biol. 201:1992;200-207.
12. Young A.S., Maritim A.C., Kariuki D.P., Stagg D.A., Wafula J.M., Mutugi J.J., Cummins J.M., Richards A.B., Burns C. Low-dose oral administration of human interferon alpha can control the development of Theileria parva infection in cattle. Parasitology. 101:1990;201-209.
13. Marinaro M., Boyaka P.N., Finkelman F.D., Kiyono H., Jackson R.J., Jirillo E., McGhee J.R. Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses. J. Exp. Med. 185:1997;415-427.
14. Baqar S., Pacheco N.D., Rollwagen F.M. Modulation of mucosal immunity against campylobacter jejuni by orally administered cytokines. Antimicrob. Agents Chemother. 37:1993;2688-2692.
15. Gotze H., Rothman S.S. Enteropancreatic recirculation of digestive enzymes as a conservation mechanism. Nature. 257:1975;607-609.
16. Leibow O., Rothman S.S. Enteropancreatic circulation of digestive enzymes. Science. 189:1975;472-474.
17. 125I-labelled trypsin in man: evidence for recirculation. Gut. 21:1980;580-586.
18. Seifert J. Quantitative examination of the resorption of trypsin, chymotrypsin, amylase, papain and pancreatin by the gastrointestinal tract following oral application. Allgemeinmedizin. 19:1990;132-137.
19. Gardner M.L.G., Steffens K.I. Absorption of orally administered enzymes. 1995;Springer-Verlag, Berlin.
20. Castell J.V., Friedrich G., Kuhn C.S., Poppe G.E. Intestinal absorption of undegraded proteins in men: presence of bromelain in plasma after oral intake. Am. J. Physiol. 273:1997;139-146.
21. Miller J.M., Ophers W. Increased proteolytic activity of human blood serum after the oral administration of bromelain. Exp. Med. Surg. 22:1964;277-280.
22. Nakazawa M., Emancipator S.N., Lamm M.E. Proteolytic enzyme treatment reduces glomerular immune deposits and proteinuria in passive Heymann nephritis. J. Exp. Med. 164:1986;1973-1987.
23. Steffen C., Menzel J. In vivo degradation of immune complexes in the kidneys via orally administered enzymes. Wien Klin. Wochenschr. 99:1987;525-527.
24. Kleine M.-W. The therapy of herpes zoster with proteolytic enzymes. Therapiewoche. 37:1987;1108-1112.
25. Kleine M.-W. A comparison between an oral hydrolytic enzyme combination and oral acyclovir as therapy of acute zoster. J. Eur. Acad. Dermatol. Venercol. 2:1993;296-307.
26. Billigmann P. Enzyme therapy - an alternative in the treatment of herpes zoster. Adv. Med. 39:1995;44-48.
27. Baumhackl U., Fordermair S. Enzyme therapy in multiple sclerosis. A preliminary report on a multicenter study. Allgemeinmedizin. 19:1990;169-172.
28. Klein G., Pollmann G., Kullich W. Clinical experience with enzyme therapy in patients with rheumatoid arthritis in comparison with gold. Allgemeinmedizin. 19:1990;144-147.
29. Lehmann P.V., Forsthuber T., Miller A., Sercarz E.E. Spreading of T cell autoimmunity to cryptic determinants of an autoantigen. Nature. 358:1992;155-157.
30. Forsthuber T., Yip H.C., Lehmann P.V. Induction of TH1 and TH2 immunity in neonatal mice. Science. 271:1996;1728-1730.
31. Bachman M.F., McKall-Faienza K., Schmits R., Bouchard D., Beach J., Speiser D.E., Mak T.W., Ohashi P.S. Distinct roles for LFA-1 and CD28 during activation of naive T cells: adhesion versus costimulation. Immunity. 7:1997;549-557.
32. Cai Z., Brunmark A., Jackson M., Loh D., Peterson P., Sprent J. Transfected Drosophila cells as a probe for defining the minimal requirements for stimulating unprimed T cells. Proc. Natl. Acad. Sci. USA. 93:1996;14736-14741.
33. +T cells. ICAM-1 or B7-1 can costimulate naive CD4 T cell activation but both are required for optimum response. J. Immunol. 155:1995;45-57.
34. Sommer F., Huber M., Rollinghoff M., Lohoff M. CD44 plays a co-stimulatory role in murine T cell activation: ligation of CD44 selectively co-stimulates IL-2 production, but not proliferation in TCR-stimulated murine Th1 cells. Int. Immunol. 7:1995;1779-1786.
35. Ashton-Rickardt P.G., Tonegawa S. A differential-avidity model for T-cell selection. Immunol. Today. 15:1994;362-366.
36. Targoni O.S., Lehmann P.V. Endogenous myelin basic protein inactivates the high avidity T cell repertoire. J. Exp. Med. 187:1998;2055-2063.
37. +T cells. J. Exp. Med. 182:1995;1591-1596.
38. +T helper cell phenotype development in a T cell receptor-αβ -transgenic model. J. Exp. Med. 182:1995;1579-1584.
39. Kuchroo V.K., Das M.P., Brown J.A., Ranger A.M., Zamvil S.S., Sobel R.A., Weiner H.L., Nabavi N., Glimcher L.H. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell. 80:1995;707-718.
40. Khoury S.J., Hancock W.W., Weiner H.L. Oral tolerance to myelin basic protein and natural recovery from experimental allergic encephalomyelitis are associated with down regulation of inflammatory cytokines and differential up regulation of transforming growth factor-β interleukin 4 and prostaglandin E expression in the brain. J. Exp. Med. 176:1992;1355-1364.
41. Gaciong Z., Paczek L., Bojakowski K., Wisniewski M., Heidland A. Beneficial effect of proteases on allograft arteriosclerosis in a rat aortic model. Nephrol. Dial. Transplant. 11:1996;987-989.
42. Schnyder J., Baggiolini M. Secretion of lysosomal hydrolases by stimulated and nonstimulated macrophages. J. Exp. Med. 148:1978;435-450.
43. Ashton-Rickardt P.G., Bandeira A., Delaney J.R., Van Kaer L., Pircher H.P., Zinkernagel R.M., Tonegawa S. Evidence for a differential avidity model of T cell selection in the thymus. Cell. 76:1994;651-663.
44. Lehmann P.V., Targoni O.S., Forsthuber T.G. Shifting T cell activation thresholds in autoimmunity and determinant spreading. Immunol. Rev. 164:1998;53-61.
45. Gordon E.J., Myers K.J., Dougherty J.P., Rosen H., Ron Y. Both anti-CD11a (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 62:1995;153-160.
46. Ebnet K., Kaldjian E.P., Anderson A.O., Shaw S. Orchestrated information transfer underlying leukocyte endothelial interactions. Annu. Rev. Immunol. 14:1996;155-177.